FOI release

Expert advice on the safety risk of the supply and use of gonadotropin-releasing hormone (GnRH)

This request was refused in part, so we didn't provide some of the information the requester asked for. This may include information where we can neither confirm nor deny that we hold it.

Case reference FOI2024/00784

Received 11 December 2024

Published 17 January 2025

Request

Please provide the independent expert advice on the safety risk of the supply and use of gonadotropin-releasing hormone (GnRH) agonist for puberty suppression in adolescants experiencing Gender incongruence of childhood that was referred to by the Department of Health and Social Care as having been provided to them (see, for example, https://news.stv.tv/scotland/puberty-blockers-for-children-with-gender-dysphoria-to-be-banned-indefinitely-in-uk).

Response

see attached

Documents

• FOI2024_00784 redacted for publication.pdf (101.1 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.